Mutational spectrum
Disease-causing variants are mostly point mutations (~70%) spread over the 7 exons, in addition to small (o60 nucleotides) and large (≥60 nucleotides) rearrangements accounting for about 28% and 2%, respectively. 1 Public lists of locus-specific DNA sequence variants are available (http://fabry-database.org; www.GalafoldAmenability Table. com)
Analytical methods
Bidirectional sequencing (Sanger) of the seven coding exons and the exon-intron boundaries. In case of females, MLPA or qPCR should be performed if no disease-causing variant has been found by Sanger sequencing. Occasionally, GLA is included in a NGS (next-generation sequencing) panel aimed to detect disease-causing variants of genes frequently implicated in various clinical conditions suggestive of Fabry disease, such as hypertrophic cardiomyopathy or terminal kidney insufficiency.
Analytical validation
Bidirectional sequencing; control of results by parallel use of alternative molecular genetic methods (eg restriction analysis, ASO-PCR etc); analysis of samples of family members (as positive and negative controls); comparison with the database entries and data in the literature; quality control through sharing samples. In the case of variants of unknown clinical significance discovered in the frame of screenings of newborns or high-risk patient cohorts, careful evaluation of pathogenic nature is mandatory.
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) One per 30 000-80 000 births for the classic phenotype. Compared to male patients, disease phenotypes in females appear usually at a later age and are less severe. 3 Echevarria and colleagues suggested that in carriers with skewed X-inactivation (allele ratios 475:25), there is a positive correlation between overall severity of clinical phenotype, allele selection and degree of X-chromosome inactivation. 4 Nevertheless, for females, a reliable diagnosis of Fabry disease can only be made by gene analysis. 
TEST CHARACTERISTICS

Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if quantification can only be made case by case.
Practically 100%
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
In case of proven disease-causing mutations, almost 100% of males and up to 80% of females develop signs and/or symptoms of the disease (unpublished data of the authors), whereas expressivity is very variable both within the same family and among different families carrying the same disease-causing variant.
2.6
Negative clinical predictive value (probability not to develop the disease if the test is negative) Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered. Index case in that family had been shown to carry a proven diseasecausing variant: Practically 100% Index case in that family had not been tested:
Depending on age and degree of relationship, ca. 98% in males and ca. 96% in females, if bidirectional sequencing of all coding exons and short adjacent intronic sequences was performed (unpublished data of the authors).
3. CLINICAL UTILITY 3.1 (Differential) diagnostics: the tested person is clinically affected (To be answered if in 1.10 'A' was marked). Male patients with the classic form of the disease have very low alphagalactosidase A activity and can be diagnosed by an enzyme assay in blood leukocytes or using dried blood spots. Some male patients with attenuated forms of the disease have considerable residual alphagalactosidase A activity (5-30%), although still far below the reference range. Diagnosis must be confirmed in all male cases by enzyme assay in blood leukocytes and DNA sequence analysis. The activity of alphagalactosidase A may be normal in female carriers. Therefore, a diagnosis of Fabry disease in females can only be made by molecular genetic tests. Before enzyme replacement therapy is initiated, the diagnosis should be verified by detection of the disease-causing variant.
Can a diagnosis be made other than through a genetic test?
The c.937G4T/p.(Asp313Tyr) change results in a serum pseudodeficiency of alpha-galactosidase A activity and is not disease-causing. Similarly, a number of GLA variants previously thought to be diseasecausing have been shown recently to be neutral or of unknown significance (see ref. 5 and references therein).
Describe the burden of alternative diagnostic methods to the patient
Small (blood sample drawing)
How is the cost effectiveness of alternative diagnostic methods to be judged?
Results of the enzyme assay are usually available within 3-7 days. Measuring enzyme activity for diagnosis (in males) costs presently significantly less than molecular genetic analysis.
Will disease management be influenced by the result of a genetic test?
No □ Yes ⊠
Therapy (please describe)
Depending on the disease-causing variant found and the clinical phenotype, enzyme replacement and/or chaperon therapy may be indicated. Adjunctive symptomatic therapeutic measures are also often necessary.
Prognosis (please describe)
Classic form of Fabry disease is a relentless progressive storage disorder. Without specific therapy, male patients as well as a subset of female patients are at risk of developing life-threatening complications.
Management (please describe)
In case of enzyme replacement therapy, lifelong intravenous infusions of recombinant alpha-galactosidase A.
3.2 Predictive setting: the tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked). In case of potential heterozygotes, the knowledge of not having an elevated carrier risk results in 'relief' with regard to the familial risk, and allows an informed decision on family planning and prenatal diagnosis.
Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?
Enzyme replacement or chaperon therapy can only be initiated if a proven disease-causing GLA variant has been detected or the mutation is 'amenable'. Since life expectancy of patients without targeted therapy is significantly reduced both in males and females, regular monitoring and timely diagnosis of disease-specific signs and symptoms are essential. The major causes of morbidity and mortality of Fabry disease are terminal kidney insufficiency, cardiovascular disease and stroke. Therefore, management of patients with Fabry disease requires a multidisciplinary team of medical sub-specialists. 6 3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.10 'C' was marked). 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe).
Gene analysis allows diagnosis of carrier state in female relatives of probands.
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